Filter By:

Reset
Thrombosis Research

Antithrombotic drugs cause bleeding, and avoiding this is as important as avoiding a heart attack or stroke. PHRI researchers, such as senior scientist John Eikelboom, are exploring whether we can separately identify risk factors that predict bleeding and others that predict stroke, in order to tailor antithrombotic therapy to the patient’s risk for either condition.

We collaborate with: the COMPASS international network of cardiologists, internists, hospitalists, vascular physicians and surgeons; the INTERBLEED network of gastroenterologists; Thrombosis and Atherosclerosis Research Institute (TaARI); and the Canadian Venous thromboembolism and Outcomes Research Network (CanVECTOR).

John Eikelboom

Senior Scientist

John Eikelboom
Senior Scientist

John Eikelboom is Professor, Department of Medicine, McMaster University, Senior Scientist, Population Health Research Institute, Hamilton Health Sciences Corporation, and Hematologist, Thrombosis Service, Hamilton General Hospital. He completed training in Internal Medicine and Hematology in Perth, Australia, in 1998 and in Health Research Methodology at McMaster University, Canada, in 2000.

He has authored or co-authored more than 800 articles in peer-reviewed journals and for the past decade has been listed annually by the Web of Science among the top 1% of cited researchers. He holds the Jack Hirsh/Population Health Research Institute Chair in Thrombosis and Atherosclerosis. His current research, supported by peer reviewed funding from the Canadian Institutes for Health Research and the Gates Foundation focuses on the efficacy and safety of antithrombotic therapies in arterial, venous, cardiac, and procedure-associated thromboembolism as well as strategies to reduce the burden of the “big three” infectious diseases (HIV, TB, malaria) on the African continent.

Stuart Connolly

Stuart Connolly is a Professor of Medicine at McMaster University and a cardiac electrophysiologist at Hamilton Health Sciences. He became a faculty member at McMaster University in 1983 and was awarded a full professorship in 1994. He was also appointed as the inaugural holder of the Salim Yusuf Chair in Cardiology at McMaster University.

He has published more than 270 scientific articles in the field, and is currently a member of the editorial boards for a number of prominent cardiology journals, including Heart, the American Heart Journal and the Journal of Pacing and Electrophysiology. His main research interests are focused on the evaluation of treatments for heart rhythm disorders. His academic career has been largely devoted to the design and execution of controlled clinical trials in this area.

He holds a Masters degree from Fordham University, New York, and an MD from McGill University in Montreal. He received his specialist training in cardiology at the University of Toronto and at Stanford University.

Vinai Bhagirath

Investigator

Vinai Bhagirath
Investigator

Vinai Bhagirath is a hematologist working clinically in benign hematology and thrombosis at the Hamilton General Hospital. He holds a Master’s degree in Medical Sciences, for which he studied molecular mediators of inflammation in sepsis, after which he trained as a clinical research fellow under the mentorship of John Eikelboom, a Senior Scientist at PHRI.

His current research interests include optimal measurement and dosing of direct oral anticoagulants, innovative digital platforms to improve trial efficiency, and predictors of bleeding.

Jackie Bosch

Scientist

Jackie Bosch
Scientist

Jackie Bosch is the Assistant Dean of the McMaster Occupational Therapy Program and a PHRI Scientist. She has a Bachelor’s degree in Occupational Therapy, a Master’s degree in Clinical Epidemiology and Biostatistics, and a PhD in Rehabilitation Science. She also serves as a Professor in the School of Rehabilitation and has an Adjunct Appointment with the University of Galway College of Medicine, Nursing, and Health Sciences.

Her research focuses on improving functional outcomes in clinical trials, particularly for stroke survivors in low-resource settings, and enhancing clinical trial methods. Bosch has taken on leadership roles in large-scale trials such as HOPE, HOPE-TOO, HOPE-3 (NCT00468923), DREAM (NCT00095654), ORIGIN (NCT00069784), TIPS-3 (NCT01646437), and COMPASS (NCT01776424). She leads the Organized Stroke Care Across Income Levels (OSCAIL) group, which has conducted a proof-of-concept study implementing key aspects of stroke unit care in hospitals within low-resource settings. Currently, the OSCAIL group is working on a community-based study aimed at improving outcomes for stroke survivors in these challenging environments. Bosch is also interested in optimizing how clinical trials are conducted, especially by finding new ways to make the start-up and execution processes more efficient.

Jackie Bosch has published 184 articles and received several awards, including the Lorna Reimer Award for Leadership from the Canadian Occupational Therapy Foundation in 2019 and the Faculty of Health Sciences, McMaster University, Programs Award for Graduate Students in 2014.

Noel Chan

Scientist

Noel Chan
Scientist

Noel Chan is an Assistant Professor in the Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, specializing in anticoagulant therapy and thrombosis medicine. His research seeks to improve our understanding of the triggers for thrombosis (including the role of inflammation) and the determinants of variable response to antithrombotic therapies to inform on novel strategies that have the potential to further reduce the burden of thrombosis.

Deborah Siegal

Associate Senior Scientist

Deborah Siegal
Associate Senior Scientist

Deborah Siegal is an Associate Professor in the Department of Medicine within the Division of Hematology at the University of Ottawa. Her primary research interests include improving patient outcomes after anticoagulant-related bleeding; management of anticoagulants in patients who have acute bleeding complications or require urgent surgery; understanding the factors that influence patient and physician decision-making after anticoagulant-related bleeding; and reducing red blood cell transfusion by minimizing iatrogenic blood loss for laboratory testing.

With expertise in the design and conduct of pragmatic cluster randomized trials, individual patient randomized trials, mixed-methods studies, observational studies and meta-analyses, Deborah Siegal has received peer-reviewed grant support as principal investigator from the Canadian Institutes of Health Research, the American Society of Hematology, CanVECTOR/Heart and Stroke Foundation of Canada, Ontario AFP Innovation Fund, and Hamilton Health Sciences Foundation. She has published 70 peer-reviewed articles including several in high-impact journals such as The New England Journal of Medicine, Circulation, Blood, and Journal of Thrombosis and Haemostasis.

Jessica Tyrwhitt

Program Manager

Jessica Tyrwhitt
Program Manager

Jessica Tyrwhitt has more than 10 years’ experience in coordinating and managing large, international clinical trials. She oversees interventional trials, registries, and observational research studies looking at primary and secondary prevention of cardiovascular disease in a variety of therapeutic areas, including cardiology, thrombosis, nephrology, cardio-oncology and diabetes.

She holds an Honours Bachelor of Science Degree & Business from the University of Waterloo.

 

Courtney Christou

Project Manager

Courtney Christou
Project Manager

Courtney has more than eight years of experience working in both industry and academic research. She primarily manages large international drug trials that focus primarily on prevention of cardiovascular disease (TIPS-3, COMPASS and ORIGIN trials) and chronic kidney disease (ACHIEVE, RECORD and DISCO-RLS trials).

She holds an Honours Bachelor of Applied Sciences with a Major in Kinesiology and a Diploma in Fitness and Health Promotion from the University of Guelph-Humber.

ongoing

ANNEXa-I

Thrombosis

ANNEXa-I is a randomized, multicenter, Phase 4 clinical trial of 440 patients designed to determine...

completed

ANNEXa-4

Thrombosis

In patients receiving a factor Xa inhibitor who are experiencing an acute major bleed, the...

ongoing

INTERBLEED

Thrombosis

Antithrombotic therapies are effective for prevention of cardiovascular (CV) events, but they cause bleeding. Emerging...

completed

STRATUS

Thrombosis

Using a stepped wedge cluster randomized trial design, the specific aim of the STRATUS study...

completed

TADA

Thrombosis

Optimization of the formulation of Pradaxa® (Dabigatran etexilate) provides consistent absorption in patients, independent of...

completed

STRATUS Pilot

Thrombosis

The STRATUS Pilot study evaluated the use of small-volume (“soft-draw”) blood collection tubes for laboratory...

Back To Top